The field of research in PD-L1 TPS changes in NSCLC is mainly dominated by retrospective studies including patients with localized/resectable disease, having received neo-adjuvant or adjuvant chemotherapy (18–24), but the results remain conflicting and controversial. This evidence concerns the gene CD274 and non-small cell lung carcinoma.